Learn
Alexander Shulgin was the greatest psychoactive chemist of the 20th century. James Kent recollects his visit to Shulgin’s lab in...
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials,...
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to...
DMT is a powerful hallucinogen famous for producing experiences of encounters with entities, but how many people actually see them?...
“This event wisely explores and intentionally focuses on living better through evidence-based science and the potential that plant and entheogenic...
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of...
Scientific discovery comes from creative insights, and a recently published review details how psychedelics can play a major role in...
Despite the LSD experience lasting only two hours, Hofmann was amazed at the power of his creation. And like any...
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind...